[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth",
    "summary": "BMY's growth-driving portfolio increased 17% year-over-year, prompting an upward revision in 2025 revenue guidance and showing signs of moving away from legacy product revenues. Read more.",
    "url": "https://finnhub.io/api/news?id=ac20997414d3db5b10d808f7f140d89a029bf2fb36b108c569bf9a997bc5c2f1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762193199,
      "headline": "Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth",
      "id": 137307958,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2230981585/image_2230981585.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BMY's growth-driving portfolio increased 17% year-over-year, prompting an upward revision in 2025 revenue guidance and showing signs of moving away from legacy product revenues. Read more.",
      "url": "https://finnhub.io/api/news?id=ac20997414d3db5b10d808f7f140d89a029bf2fb36b108c569bf9a997bc5c2f1"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold",
    "summary": "BioNTech SE shared its Q3 earnings, business updates, and guidance for 2025 earlier today. Click here to find out why BNTX stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=f45077d6542719df4a9e9a70ace1c79862cf71dd410e44465afba8469f53cedf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762177451,
      "headline": "BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold",
      "id": 137305635,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BioNTech SE shared its Q3 earnings, business updates, and guidance for 2025 earlier today. Click here to find out why BNTX stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=f45077d6542719df4a9e9a70ace1c79862cf71dd410e44465afba8469f53cedf"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025",
    "summary": "PRINCETON, N.J., November 03, 2025--Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions",
    "url": "https://finnhub.io/api/news?id=e8a63da9444ec38aef4607e00fe746954bfdced230d025ee6b00babc299bbfdd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762171140,
      "headline": "Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025",
      "id": 137303108,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., November 03, 2025--Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions",
      "url": "https://finnhub.io/api/news?id=e8a63da9444ec38aef4607e00fe746954bfdced230d025ee6b00babc299bbfdd"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update",
    "summary": "Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging anti-tumor activity and manageable safety profile of pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L11 and VEGF-A, in first disclosed interim data from global Phase 2 trial in extensive-stage small cell lung cancer Plan to initiate additional pivotal t",
    "url": "https://finnhub.io/api/news?id=c11a09f6c03d2ab1d13cc980f495572176d9aee59c0b87e9a92da98b426e2414",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762170300,
      "headline": "BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update",
      "id": 137303109,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging anti-tumor activity and manageable safety profile of pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L11 and VEGF-A, in first disclosed interim data from global Phase 2 trial in extensive-stage small cell lung cancer Plan to initiate additional pivotal t",
      "url": "https://finnhub.io/api/news?id=c11a09f6c03d2ab1d13cc980f495572176d9aee59c0b87e9a92da98b426e2414"
    }
  },
  {
    "ts": null,
    "headline": "United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb",
    "summary": "Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and",
    "url": "https://finnhub.io/api/news?id=2eadee4000155ed6b35aa4437da7c0e07a6decf3ae51676f37ee5680c157fe29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762164720,
      "headline": "United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb",
      "id": 137302169,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and",
      "url": "https://finnhub.io/api/news?id=2eadee4000155ed6b35aa4437da7c0e07a6decf3ae51676f37ee5680c157fe29"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes",
    "summary": "PRINCETON, N.J., November 03, 2025--Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes",
    "url": "https://finnhub.io/api/news?id=7b7516c30dba48d3936547c9c912b00dd9edd0fde4a0cc060f106af536741342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762163700,
      "headline": "Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes",
      "id": 137303111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., November 03, 2025--Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes",
      "url": "https://finnhub.io/api/news?id=7b7516c30dba48d3936547c9c912b00dd9edd0fde4a0cc060f106af536741342"
    }
  }
]